Pharmacokinetics and circulating VEGF, VEGFR2, HGF, and MET levels were evaluated in patients taking the combination of pazopanib and tivantinib; tumor pharmacodynamic responses were assessed in patients receiving only pazopanib for 7 days prior to initiating combination therapy. This evidence concerns the gene VEGFA and neoplasm.